Thor Medical ASA has signed a five-year frame agreement to supply NucliThera AS with thorium-228 (Th-228). The isotope will be used in NucliThera’s development programs for hematological cancers. Led by Dr. Roy H. Larsen and Professor Emeritus Øyvind S. Bruland, NucliThera’s research team is advancing an early-stage development program targeting hematological cancers such as lymphoma…

NucliThera AS has engaged Ada Repetto-Llamazares as Chief Scientific Officer as of February 1, 2025.Ada Repetto-Llamazares, PhD, is an accomplished leader in radiopharmaceutical development, combining over 15 years of hands-on expertise in advancing radioligand therapies with a strong foundation in nuclear physics and dual PhDs—a PhD in radioligand therapy from the University of Oslo and…